<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878057</url>
  </required_header>
  <id_info>
    <org_study_id>2016YJZ19</org_study_id>
    <nct_id>NCT02878057</nct_id>
  </id_info>
  <brief_title>Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)</brief_title>
  <official_title>Multicenter Phase II Study of Apatinib in Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of the patients with recurrent and metastatic breast cancer remains a major&#xD;
      problem. There is still a lack of effective targeted therapy for Her-2 negative breast&#xD;
      cancer.Based on the present researches on the anti-angiogenesis drugs in advanced breast&#xD;
      cancer, the investigators believe that it is necessary to further explore the efficacy and&#xD;
      safety of apatinib in advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the comprehensive treatment of breast cancer wildly used in the clinical practice, the&#xD;
      life quality of the patients with breast cancer has been improved greatly, and the survival&#xD;
      of the patients has been extended as well. However, the treatment of the patients with&#xD;
      recurrent and metastatic breast cancer remains a major problem. There is still a lack of&#xD;
      effective targeted therapy for Her-2 negative breast cancer.&#xD;
&#xD;
      Based on the present researches on the anti-angiogenesis drugs in advanced breast cancer, the&#xD;
      investigators believe that it is necessary to further explore the efficacy and safety of&#xD;
      apatinib in advanced breast cancer. The aim of this research is to evaluate the&#xD;
      progression-free survival (PFS) of the patients with HER-2 negative advanced breast cancer&#xD;
      with chest wall metastasis in the treatment of apatinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">September 2, 2020</completion_date>
  <primary_completion_date type="Actual">September 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>evaluation per 2 cycles (8 weeks), up to 6 months;From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
    <description>survival from first dose to death or last follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective response rate = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression Disease (PD), &gt;=20% increase in the sum of the longest diameter of target lesions or appearance of new lesions; Stable Disease (SD), between PR and PD.&#xD;
Disease control rate (DCR) = CR + PR + SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
    <description>all kind of adverse events, including hypertension, proteinuria, nausea, fatigue, and bilirubin increase.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
    <arm_group_label>Advanced Breast Cancer</arm_group_label>
    <other_name>Apatinib Mesylate Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HER-2 negative advanced breast cancer with chest wall metastasis confirmed by&#xD;
             histology or cytological examination (patients who have received anthracyclines and/or&#xD;
             paclitaxel in adjuvant chemotherapy).&#xD;
&#xD;
          2. Patients with recurrence or metastasis who have received no more than two lines of&#xD;
             chemotherapy.&#xD;
&#xD;
          3. If hormone receptor is positive, endocrine therapy must have been performed for the&#xD;
             patients with recurrence or metastasis, or the recurrence or metastasis occurred in&#xD;
             less than two years of endocrine therapy.&#xD;
&#xD;
          4. ≥ 18 years old.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          6. A life expectancy of more than 3 months.&#xD;
&#xD;
          7. At least one measurable site of disease confirmed by CT or MRI according to Response&#xD;
             Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria was required.&#xD;
&#xD;
          8. If the target lesions are lymph nodes, the short diameter is required to be less than&#xD;
             1.5cm and the target lesions are not suitable for surgical treatment; target lesions&#xD;
             have not been in radiotherapy or recurred in the radiation field.&#xD;
&#xD;
          9. Baseline blood routine examination in accordance with the following criteria:&#xD;
             neutrophil counts more than 1.5*109/L; platelet counts greater than 100*109/L;&#xD;
             hemoglobin greater than 9 g/dL (blood transfusion is allowed to achieve or maintain&#xD;
             the index)&#xD;
&#xD;
         10. Liver function in accordance with the following criteria: total bilirubin less than&#xD;
             1.5 times the upper limit of normal value; aspartate aminotransferase (AST), alanine&#xD;
             aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than&#xD;
             5 times the upper limit of normal value in patients with liver metastases.&#xD;
&#xD;
         11. Renal function in accordance with the following criteria: serum creatinine less than&#xD;
             1.25 times the upper limit of normal value, or the creatinine clearance rate&#xD;
             calculated greater than 50 mL/min;&#xD;
&#xD;
         12. Women with fertility are willing to take contraceptive measures in the trial: when&#xD;
             seven days before the drug delivery of serum or urine pregnancy test negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. receiving radiation therapy 28 days before enrolled. Radiotherapy before enrollment to&#xD;
             relieve the metastatic bone pain is allowed, but medullary bone radiated should not&#xD;
             exceed 30% of the total amount;&#xD;
&#xD;
          2. symptomatic central nervous system metastases;&#xD;
&#xD;
          3. current or recent (30 days before enrollment) use of another study drug or being&#xD;
             involved in another clinical study;&#xD;
&#xD;
          4. Other malignant tumors that have occurred within 5 years (except for the cured or&#xD;
             well-controlled cervical carcinoma in situ, skin squamous cell carcinoma, or skin&#xD;
             basal cell carcinoma);&#xD;
&#xD;
          5. With hypertension and the blood pressure cannot be reduced to the normal range through&#xD;
             antihypertensive drug treatment (systolic blood pressure greater than or equal to 140&#xD;
             mmHg or diastolic blood pressure greater than or equal to 90 mmHg).&#xD;
&#xD;
          6. With grade II or higher myocardial ischemia or myocardial infarction, poorly&#xD;
             controlled arrhythmia (including QTc interval more than or equal to 450 ms for men,&#xD;
             more than or equal to 470 ms for female);&#xD;
&#xD;
          7. according to the criteria of NYHA, cardiac insufficiency of grade III and IV or left&#xD;
             ventricular ejection fraction (LVEF) less than 50% revealed by echocardiography;&#xD;
&#xD;
          8. abnormal coagulation function (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN+4 seconds or&#xD;
             APTT &gt;1.5 times the ULN), with bleeding tendency or under thrombolysis or&#xD;
             anticoagulation therapy;&#xD;
&#xD;
          9. within 3 months before enrollment, clinically significant bleeding symptoms occur, or&#xD;
             having obvious bleeding tendency, such as gastrointestinal bleeding, bleeding gastric&#xD;
             ulcer, occult blood + + and above in baseline period, or suffering from vasculitis, et&#xD;
             al;&#xD;
&#xD;
         10. within 4 months before enrollment receiving major surgery or getting severe traumatic&#xD;
             injury, fracture or ulcer;&#xD;
&#xD;
         11. having factors that affect the absorption of the oral drugs obviously, such as the&#xD;
             inability to swallow, chronic diarrhea and intestinal obstruction, et al;&#xD;
&#xD;
         12. urine routine test with urinary protein more than ++, or 24 hour urinary protein more&#xD;
             than 1.0 g;&#xD;
&#xD;
         13. with symptomatic serous cavity effusion, which needs to be surgically managed&#xD;
             (including pleural effusion, ascites, pericardial effusion);&#xD;
&#xD;
         14. with other possible conditions that can affect the clinical research or evaluation of&#xD;
             the results judged by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiping Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991 Jan 3;324(1):1-8.</citation>
    <PMID>1701519</PMID>
  </reference>
  <reference>
    <citation>D'Agostino RB Sr. Changing end points in breast-cancer drug approval--the Avastin story. N Engl J Med. 2011 Jul 14;365(2):e2. doi: 10.1056/NEJMp1106984. Epub 2011 Jun 27.</citation>
    <PMID>21707384</PMID>
  </reference>
  <reference>
    <citation>Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27;357(26):2666-76.</citation>
    <PMID>18160686</PMID>
  </reference>
  <reference>
    <citation>Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3239-47. doi: 10.1200/JCO.2008.21.6457. Epub 2010 May 24.</citation>
    <PMID>20498403</PMID>
  </reference>
  <reference>
    <citation>Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.</citation>
    <PMID>21383283</PMID>
  </reference>
  <reference>
    <citation>Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.</citation>
    <PMID>20063120</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <results_first_submitted>September 7, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2021</results_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Li Huiping</investigator_full_name>
    <investigator_title>Head of the department of breast oncology</investigator_title>
  </responsible_party>
  <keyword>Apatinib</keyword>
  <keyword>HER-2 Negative</keyword>
  <keyword>Chest wall Metastasis</keyword>
  <keyword>Multicenter Phase II Study</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all information will shared with IPD or other researhers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Dec. 2020</ipd_time_frame>
    <ipd_access_criteria>published journal</ipd_access_criteria>
    <ipd_url>https://www.baidu.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02878057/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>finished recritment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Advanced Breast Cancer</title>
          <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Advanced Breast Cancer</title>
          <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;&#xD;
Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" lower_limit="35" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lines of Chemotherapy Prior to Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>evaluation per 2 cycles (8 weeks), up to 6 months;From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Advanced Breast Cancer</title>
            <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="2.1" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>survival from first dose to death or last follow up</description>
        <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
        <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Breast Cancer</title>
            <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>survival from first dose to death or last follow up</description>
          <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="3" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective response rate = CR + PR.</description>
        <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
        <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Breast Cancer</title>
            <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective response rate = CR + PR.</description>
          <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression Disease (PD), &gt;=20% increase in the sum of the longest diameter of target lesions or appearance of new lesions; Stable Disease (SD), between PR and PD.&#xD;
Disease control rate (DCR) = CR + PR + SD.</description>
        <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
        <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Breast Cancer</title>
            <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression Disease (PD), &gt;=20% increase in the sum of the longest diameter of target lesions or appearance of new lesions; Stable Disease (SD), between PR and PD.&#xD;
Disease control rate (DCR) = CR + PR + SD.</description>
          <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis;</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>all kind of adverse events, including hypertension, proteinuria, nausea, fatigue, and bilirubin increase.</description>
        <time_frame>evaluation per 2 cycles (8 weeks), up to 55 months</time_frame>
        <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Breast Cancer</title>
            <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>all kind of adverse events, including hypertension, proteinuria, nausea, fatigue, and bilirubin increase.</description>
          <population>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, an median of 18 months</time_frame>
      <desc>The apatinib dose given was reduced from 500mg to 250mg for 60% of patients because of side effects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Advanced Breast Cancer</title>
          <description>Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)&#xD;
Apatinib: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Transaminase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Huiping Li</name_or_title>
      <organization>Department of Breast Oncology, Peking University Cancer Hospital and Institute</organization>
      <phone>86-10-88196739</phone>
      <email>huipingli2012@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

